Cargando…
晚期非小细胞肺癌BRAF突变靶向治疗进展
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105358/ https://www.ncbi.nlm.nih.gov/pubmed/30172272 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.10 |
| _version_ | 1783349647315566592 |
|---|---|
| collection | PubMed |
| description | Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC. |
| format | Online Article Text |
| id | pubmed-6105358 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-61053582018-08-27 晚期非小细胞肺癌BRAF突变靶向治疗进展 Zhongguo Fei Ai Za Zhi 综述 Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC. 中国肺癌杂志编辑部 2018-08-20 /pmc/articles/PMC6105358/ /pubmed/30172272 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.10 Text en 版权所有©《中国肺癌杂志》编辑部2018 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 综述 晚期非小细胞肺癌BRAF突变靶向治疗进展 |
| title | 晚期非小细胞肺癌BRAF突变靶向治疗进展 |
| title_full | 晚期非小细胞肺癌BRAF突变靶向治疗进展 |
| title_fullStr | 晚期非小细胞肺癌BRAF突变靶向治疗进展 |
| title_full_unstemmed | 晚期非小细胞肺癌BRAF突变靶向治疗进展 |
| title_short | 晚期非小细胞肺癌BRAF突变靶向治疗进展 |
| title_sort | 晚期非小细胞肺癌braf突变靶向治疗进展 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105358/ https://www.ncbi.nlm.nih.gov/pubmed/30172272 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.10 |
| work_keys_str_mv | AT wǎnqīfēixiǎoxìbāofèiáibraftūbiànbǎxiàngzhìliáojìnzhǎn AT wǎnqīfēixiǎoxìbāofèiáibraftūbiànbǎxiàngzhìliáojìnzhǎn |